Vanadyl Sulfate
Vanadyl sulfate is a vanadium compound popular in the 1990s as an insulin-mimetic glucose-disposal agent claimed to increase muscle fullness and glucose uptake. It has insulin-like activity in animal and cell models, but human body-composition evidence is weak and high doses raise toxicity concerns.
01 Overview
Vanadium salts can mimic insulin in vitro and in rodents, largely by inhibiting protein tyrosine phosphatases that normally dampen insulin-receptor signalling. This drove its 1990s reputation as a natural glucose-disposal agent.
Human studies show only modest and inconsistent effects on glucose or body composition, and meaningful benefit typically requires doses that risk gastrointestinal and potential organ toxicity. It remains a legal supplement but is little used today.
02 Mechanism
Inhibits protein tyrosine phosphatases (notably PTP1B), prolonging insulin-receptor and downstream signalling and mimicking some insulin actions on glucose uptake; effects are weak relative to insulin.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Supplement | 10–50 mg/day | Oral | Elemental vanadium; higher doses raise toxicity risk |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Insulin-mimetic glucose uptakeMimics some insulin actions on glucose disposal in cell and animal models. | Preclinical | ||
| Improved glucose control in diabeticsSmall human studies show minor fasting-glucose improvements, mainly in type 2 diabetes. | Modest / inconsistent | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Gastrointestinal upsetNausea, cramping and diarrhoea, especially at higher doses. | Mild | Common | Observational | |
| Vanadium accumulation / toxicityVanadium accumulates in tissues; chronic high intake raises concern for renal, hepatic and haematologic toxicity. | Moderate | Rare | Preclinical |